Delta sleep-inducing peptide supplied in solution — a presentation that matters for a nonapeptide with no stabilising modification.
- Contains
- DSIP (sequence, formula and CAS number are on the vial product page)
- Content
- 15mg in a metered 15ml bottle
- Presentation
- ready-to-use metered intranasal solution; no reconstitution step
- Purity
- ≥99% by HPLC, identity confirmed by mass spectrometry
- Released against
- the Certificate of Analysis for its own batch
About DSIP Nasal Spray
This supplies DSIP, the nonapeptide isolated from cerebral venous blood during slow-wave sleep, in a metered 15ml intranasal bottle.
DSIP is one of the less robust sequences in the catalogue, with no stabilising tail or substitution. A prepared solution filled under controlled conditions avoids the bench-side reconstitution of a fragile short peptide, which is where avoidable loss usually occurs.
What the research covers
Research context matches the vial: sleep architecture measured by EEG, with slow-wave proportion and latency as the endpoints that address the claim the compound is named for, plus secondary strands on corticotropin modulation and nociceptive thresholds.
The replication record for the original sleep findings is mixed, and that remains the honest framing regardless of presentation. The cognitive and sleep research peptides hub covers this group.
Handling DSIP Nasal Spray
Supplied as a metered preparation, so there is no reconstitution step and no reconstitution error, and no opportunity to set the concentration.
Store cold, upright and away from light. A peptide already in solution has a shorter usable life than a sealed lyophilised vial; this format trades shelf stability for immediate usability.
Other formats
The same compound is supplied as a lyophilised DSIP vial, which gives control over concentration that a fixed solution cannot.
Common questions about DSIP Nasal Spray
Is this the same compound as the DSIP vial?
Yes. The compound is identical; it is supplied already in solution in a metered intranasal bottle instead of as a lyophilised powder.
When is the nasal spray the better choice?
When the intranasal route is itself part of the study design, or when consistency between sessions matters more than control over concentration.
When is the vial the better choice?
When the protocol needs to set its own concentration or run dose-ranging. A fixed-concentration solution cannot be varied.
How long does the spray remain usable?
A peptide in solution has a shorter usable life than a sealed lyophilised vial. Keep the bottle cold, upright and protected from light, and treat its life as limited.
